Alopecia areata: burden of disease, approach to treatment, and current unmet needs.

Alhanshali L, Buontempo MG, Lo Sicco KI, et al. Clin Cosmet Investig Dermatol. 2023;16:803-820.

Clinical and genetic aspects of alopecia areata: a cutting edge review.

Ho C-Y, Wu C-Y, Chen JY-F, et al. Genes. 2023;14(7):1362.

Efficacy and safety of ritlecitinib in adolescents with alopecia areata: results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial.

Hordinsky M, Hebert AA, Gooderham M, et al. Pediatr Dermatol. 2023;40(6):1003-1009.

Development of the alopecia areata scale for clinical use: results of an academic-industry collaborative effort.

King BA, Mesinkovska NA, Craiglow B, et al. J Am Acad Dermatol. 2022;86(2):359-364.

Two phase 3 trials of baricitinib for alopecia areata.

King B, Ohyama M, Kwon O, et al. N Engl J Med. 2022;386(18):1687-1699.

When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials.

King B, Shapiro J, Ohyama M, et al. Br J Dermatol. 2023;189(6):666-673.

Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.

King B, Zhang X, Harcha WG, et al. Lancet. 2023;401(10387):1518-1529.

Cultural competence for the 21st century dermatologist practicing in the United States.

McKesey J, Berger TG, Lim HW, et al. J Am Acad Dermatol. 2017;77(6):1159-1169.

Burden of illness in alopecia areata: a cross-sectional online survey study.

Mesinkovska N, King B, Mirmirani P, et al. J Investig Dermatol Symp Proc. 2020;20(1):S62-S68.

The burden of alopecia areata: A scoping review focusing on quality of life, mental health and work productivity.

Muntyanu A, Gabrielli S, Donovan J, et al. J Eur Acad Dermatol Venereol. 2023;37(8):1490-1520.

Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation.

Olsen E, Hordinsky M, McDonald-Hull S, et al. J Am Acad Dermatol. 1999;40(2 Pt 1):242-246.

Quality of life in children and adolescents with alopecia areata—a systematic review.

Prendke M, Kanti-Schmidt V, Wilborn D, et al. J Eur Acad Dermatol Venereol. 2023;37(8):1521-

1534.

Alopecia areata: an updated review for 2023.

Sibbald C. J Cutan Med Surg. 2023;27(3):241-259.

Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options.

Sterkens A, Lambert J, Bervoets A. Clin Exp Med. 2021;21(2):215-230.

Baricitinib safety for events of special interest in populations at risk: analysis from randomised trial data across rheumatologic and dermatologic indications.

Taylor PC, Bieber T, Alten R, et al. Adv Ther. 2023;40(4):1867-1883.

Efficacy of baricitinib in patients with various degrees of alopecia areata severity: post-hoc analysis from BRAVE AA1 and BRAVE AA2.

Taylor S, Korman NJ, Tsai TF, et al. Dermatol Ther (Heidelb). 2023;13(12):3181-3191.

The role of serum Th1, Th2, and Th17 cytokines in patients with alopecia areata: clinical implications.

Waśkiel-Burnat A, Osińska M, Salińska A, et al. Cells. 2021;10(12):3397.